Yan Li

Summary

Affiliation: AstraZeneca R and D

Publications

  1. doi request reprint In vitro assessment of metabolic drug–drug interaction potential of AZD2624, neurokinin-3 receptor antagonist, through cytochrome P(450) enzyme identification, inhibition, and induction studies
    Yan Li
    Discovery DMPK, AstraZeneca Pharmaceuticals, Wilmington, Delaware, USA
    Xenobiotica 40:721-9. 2010
  2. doi request reprint Disposition and metabolism of ticagrelor, a novel P2Y12 receptor antagonist, in mice, rats, and marmosets
    Yan Li
    Drug Metabolism and Pharmacokinetics, AstraZeneca R and D, Waltham, MA 02451, USA
    Drug Metab Dispos 39:1555-67. 2011
  3. doi request reprint Risk assessment and mitigation strategies for reactive metabolites in drug discovery and development
    Richard A Thompson
    Discovery DMPK, AstraZeneca R and D Molndal, SE 413 83 Mölndal, Sweden
    Chem Biol Interact 192:65-71. 2011

Collaborators

  • Scott W Grimm
  • Diansong Zhou
  • Richard A Thompson
  • Richard Weaver
  • J Gerry Kenna
  • Lars Weidolf
  • Alf Claesson
  • Hugues Dolgos
  • Ken Page
  • Emre M Isin
  • Ian Wilson

Detail Information

Publications3

  1. doi request reprint In vitro assessment of metabolic drug–drug interaction potential of AZD2624, neurokinin-3 receptor antagonist, through cytochrome P(450) enzyme identification, inhibition, and induction studies
    Yan Li
    Discovery DMPK, AstraZeneca Pharmaceuticals, Wilmington, Delaware, USA
    Xenobiotica 40:721-9. 2010
    ..However, metabolism of AZD2624 might be inhibited when co-administrated with potent CYP3A4/5 inhibitors...
  2. doi request reprint Disposition and metabolism of ticagrelor, a novel P2Y12 receptor antagonist, in mice, rats, and marmosets
    Yan Li
    Drug Metabolism and Pharmacokinetics, AstraZeneca R and D, Waltham, MA 02451, USA
    Drug Metab Dispos 39:1555-67. 2011
    ..Ticagrelor, AR-C124910, and AR-C133913 were the major components found in feces from the three species examined. Overall, in vivo metabolite profiles were qualitatively similar across all species and consistent with in vitro results...
  3. doi request reprint Risk assessment and mitigation strategies for reactive metabolites in drug discovery and development
    Richard A Thompson
    Discovery DMPK, AstraZeneca R and D Molndal, SE 413 83 Mölndal, Sweden
    Chem Biol Interact 192:65-71. 2011
    ..We exemplify the potential value of this approach by consideration of the thiazolidinedione class of drugs...